摘要
目的评价国产艾滋病抗病毒药物治疗吸毒成瘾艾滋病病毒感染者/病人(HIV/AIDS)的疗效及对治疗时机的探讨。方法采用回顾性研究方法,调查随访2004～2007年在北京佑安医院确诊并经抗病毒治疗的吸毒成瘾HIV/AIDS患者114例,按照疾病进展将随访对象分成艾滋病组(AIDS)和HIV感染组(freeofAIDS),所有患者均用3种抗病毒药物(奈韦拉平+司他夫定+拉米夫定)治疗,疗程48周。常规方法检测患者治疗前后血CD4+T淋巴细胞数,核酸序列扩增技术(NASBA)测定病毒载量。结果114例吸毒成瘾HIV/AIDS患者CD4细胞数平均增加(182.39±90.70)个/mm3;其中35例吸毒成瘾HIV/AIDS患者中85.71%病毒载量下降至50copies/ml以下,下降2.5个Log数;艾滋病组与HIV感染组治疗后3、6、9和12个月CD4+T淋巴细胞差异有统计学意义(P<0.05);治疗6个月后,HIV感染组病毒载量下降趋势较艾滋病组明显,但治疗12个月后HIV感染组病毒载量较艾滋病组有反弹现象。结论吸毒成瘾HIV/AIDS患者选用国产艾滋病抗病毒药物奈韦拉平+司他夫定+拉米夫定治疗取得良好效果,并且对艾滋病患者的疗效好于HIV感染者。
Objective To evaluate the efficacy of China-made ARVs in treating drug-addicted people living with HIV/AIDS（PLHA） and explore the appropriate time of treatment initiation.Methods Retrospective study was used to survey and follow up 114 drug-addicted PLHA who were identified in Beijing You＇an Hospital between 2004 and 2007 and received 48-week ART.These PLHA were classified as AIDS patients or HIV infected persons（i.e.free of AIDS） according to the stage of disease progression.All PLHA received the same ART regimen consisting of three ARVs（i.e.NVP＋D4T＋3TC）.Routine tests were performed to measure CD4 ＋ T-lymphocyte count before and after ART.Nucleic acid sequence-based amplification（NASBA） was used to test the viral load（VL）.Results CD4＋T cell count showed an average increase of（182.39±90.70）/mm3 among the 114 drug-addicted PLHA.Viral load declined to less than 50 copies/ml in 85.71% of 35 drug addicted PLHA,with a decline of 2.5 logs.There was an evident difference of statistical significance in CD4＋T-lymphocyte count between AIDS patients and HIV infected persons（P〈0.05）.At 6 months,HIV infected persons had a more obvious decreasing trend in viral load than AIDS patients,but experienced a rebound in viral load at 12 months.Conclusion The use of China-made ARVs（NVP＋D4T＋3TC） in treating drug-addicted PLHA achieved good results.The efficacy was better in AIDS patients than in HIV infected persons.
出处
《中国病原生物学杂志》
CSCD
2008年第8期567-569,573,共4页
Journal of Pathogen Biology
基金
北京市科委科技计划重大项目-艾滋病高危人群监测
筛查及防控策略研究课题资助(NoD0906003040591)
